Phase 1 Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment

By sjmartinez • June 27, 2023

Roschewski M, Patel MR, Reagan PM, Saba NS, Collins GP, Arkenau HT, de Vos S, Nuttall B, Acar M, Burke K, White RD, Udriste M, Sharma S, Dougherty B, Stetson D, Jenkins D, Mortlock A, Forcina A, Munugalavadla V, Flinn I. Phase 1 Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment. Clin Cancer Res. 2023 Jun 26:CCR-22-2483. doi: 10.1158/1078-0432.CCR-22-2483. Epub ahead of print. PMID: 37364001.

Tags: Hematology/Oncology, Publications

Clinical Outcomes of Lentiviral Vector Gene Therapy for Sickle Cell Disease

Prueksapraopong C, Fernandes A, Campo Fernandez B, Roy S, Hollis RP, Habtemariam B, Pellin D, Ceoldo G, Lin TY, Dang TT, Cornetta K, Romero Z,[...]

Sustained Effects of a 6-Week Resiliency Program for Women with Metastatic Breast Cancer: A Brief Report of a Clinical Trial

Henneghan A, Wertheimer J, Kim S, Gresham G, Shirazipour CH, Jones B, Asher A. Sustained Effects of a 6-Week Resiliency Program for Women with Metastatic[...]

Retrospective study of antimicrobial prophylaxis and infections in patients with acute myeloid leukemia

Jang J, Nold T, Marshalek JP, Matthiesen J, Tomassetti S. Retrospective study of antimicrobial prophylaxis and infections in patients with acute myeloid leukemia. J Oncol[...]